AOMs result in 8% relative risk reduction in any CVD events in patients with obesityThe utilisation of anti-obesity medications (AOMs) among people with obesity could potentially alleviate the high prevalence of...
Factors associated with long-term use of FDA-approved anti-obesity medicationsOnly 19% of the patients continued to use the anti-obesity medications (AOMs) one year after their initial prescriptions and patients...
Phenomix Sciences and InformedDNA enter partnership to advance genetics-driven obesity care14 hours ago
Banded-RYGB associated with statistically significant increases in percentage excess weight loss at five years16 hours ago